Literature DB >> 18565858

Cancer immunotherapy--the endgame begins.

Louis M Weiner1.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18565858      PMCID： PMC2728623          DOI： 10.1056/NEJMp0803663

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

1.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

2.  IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.

Authors:  V Shankaran; H Ikeda; A T Bruce; J M White; P E Swanson; L J Old; R D Schreiber
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

3.  Immunotherapy of cancer: the end of the beginning?

Authors:  J R Durant
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

4.  Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.

Authors:  R A Miller; D G Maloney; R Warnke; R Levy
Journal:  N Engl J Med       Date:  1982-03-04       Impact factor: 91.245

Review 5.  Immunosuppressive strategies that are mediated by tumor cells.

Authors:  Gabriel A Rabinovich; Dmitry Gabrilovich; Eduardo M Sotomayor
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

6.  Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.

Authors:  Wen-Kai Weng; Ronald Levy
Journal:  J Clin Oncol       Date:  2003-09-15       Impact factor: 44.544

7.  Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose.

Authors:  W R Drobyski; C A Keever; M S Roth; S Koethe; G Hanson; P McFadden; J L Gottschall; R C Ash; P van Tuinen; M M Horowitz
Journal:  Blood       Date:  1993-10-15       Impact factor: 22.113

8.  Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy.

Authors:  Clare Taylor; Dawn Hershman; Nina Shah; Nicole Suciu-Foca; Dan P Petrylak; Robert Taub; Linda Vahdat; Bin Cheng; Mark Pegram; Keith L Knutson; Raphael Clynes
Journal:  Clin Cancer Res       Date:  2007-09-01       Impact factor: 12.531

9.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245
  9 in total
  16 in total

1.  Nanoengineering of Immune Cell Function.

Authors:  Keyue Shen; Michael C Milone; Michael L Dustin; Lance C Kam
Journal:  Mater Res Soc Symp Proc       Date:  2009-01-01

Review 2.  Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.

Authors:  Michael R Olin; G Elizabeth Pluhar; Brian M Andersen; Rob Shaver; Nate N Waldron; Christopher L Moertel
Journal:  Crit Rev Immunol       Date:  2014       Impact factor: 2.214

Review 3.  Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.

Authors:  Dalal AlDeghaither; Brandon G Smaglo; Louis M Weiner
Journal:  J Clin Pharmacol       Date:  2015-03       Impact factor: 3.126

Review 4.  Mechanisms of tumor resistance to EGFR-targeted therapies.

Authors:  Elizabeth A Hopper-Borge; Rochelle E Nasto; Vladimir Ratushny; Louis M Weiner; Erica A Golemis; Igor Astsaturov
Journal:  Expert Opin Ther Targets       Date:  2009-03       Impact factor: 6.902

5.  Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models.

Authors:  Natalie Kronik; Yuri Kogan; Moran Elishmereni; Karin Halevi-Tobias; Stanimir Vuk-Pavlović; Zvia Agur
Journal:  PLoS One       Date:  2010-12-08       Impact factor: 3.240

6.  PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells.

Authors:  Wenshi Wang; Roy Lau; Daohai Yu; Weiwei Zhu; Alan Korman; Jeffrey Weber
Journal:  Int Immunol       Date:  2009-08-03       Impact factor: 4.823

7.  Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma.

Authors:  Aaron J Schetter; Giang Huong Nguyen; Elise D Bowman; Ewy A Mathé; Siu Tsan Yuen; Jason E Hawkes; Carlo M Croce; Suet Yi Leung; Curtis C Harris
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

8.  Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.

Authors:  Aurélien Marabelle; Holbrook Kohrt; Idit Sagiv-Barfi; Bahareh Ajami; Robert C Axtell; Gang Zhou; Ranjani Rajapaksa; Michael R Green; James Torchia; Joshua Brody; Richard Luong; Michael D Rosenblum; Lawrence Steinman; Hyam I Levitsky; Victor Tse; Ronald Levy
Journal:  J Clin Invest       Date:  2013-06       Impact factor: 14.808

Review 9.  Anaplastic lymphoma kinase: an oncogene for tumor vaccination.

Authors:  Cristina Mastini; Cinzia Martinengo; Giorgio Inghirami; Roberto Chiarle
Journal:  J Mol Med (Berl)       Date:  2009-03-30       Impact factor: 4.599

10.  DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.

Authors:  Wim Maes; Georgina Galicia Rosas; Bert Verbinnen; Louis Boon; Steven De Vleeschouwer; Jan L Ceuppens; Stefaan W Van Gool
Journal:  Neuro Oncol       Date:  2009-03-31       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.